Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Dermatological Conditions

    EU Partner

    An Introduction to Dermatological Conditions

    Autoimmunity and deregulation of the immune system contribute to many skin diseases including systemic sclerosis, dermatomyositis, psoriasis, vitiligo, alopecia areata and lichen sclerosus; as well as inflammatory diseases such as hidradenitis suppurativa, allergic contact dermatitis and atopic eczema; and also autoimmune blistering diseases, including pemphigus vulgaris, bullous pemphigoid, epidermolysis bullosa acquisita and dermatitis herpetiformis. Established treatments include systemic corticosteroids and immunosuppressive therapies, while new therapies in development include biologic therapies targeting cytokines such as tumour necrosis factor alpha (TNF-alpha) and interleukins IL-23 and IL-17; enzymes such as Janus kinase-1 (JAK-1); and the regulatory proteinretinoic acid receptor-related-orphan-receptor-gamma t (RORγt).

    Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Dermatological Conditions Content

    Atopic Dermatitis, Dermatological Conditions, Paediatric Dermatology
    Watch Time: 39 mins
    touchIN CONVERSATION
    Treating moderate-to-severe atopic dermatitis in children and adolescents: Insights from the experts
    CE/CME ACCREDITED Prof. Dr. med. Diamant Thaçi, Dr Benjamin Ungar Translations available:

    Watch expert dermatologists discuss the management of moderate-to-severe AD in children and adolescents.

    Learning objectives
    Learning Objectives
    • Assess disease burden in paediatric patients with atopic dermatitis, including those affected on the hands and feet
    • Select systemic therapies for individual paediatric patients with moderate-to-severe atopic dermatitis based on the latest efficacy and safety data in the context of patient-specific factors
    • Apply effective strategies for monitoring and managing key side effects associated with systemic therapies for moderate-to-severe atopic dermatitis in paediatric patients
    Allergic Conditions, Dermatological Conditions, Immunology, Haematological Disorders, Urticaria
    Watch Time: 52 mins
    touchPANEL DISCUSSION
    Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
    CE/CME ACCREDITED Prof. Dr Vito Sabato, Dr Sigurd Broesby-Olsen, Prof. Prithviraj Bose Translations available:

    Multidisciplinary experts discuss the diagnosis and management of patients with systemic mastocytosis.

    Learning objectives
    Learning Objectives
    • Describe the signs, symptoms and diagnostic pathway for systemic mastocytosis
    • Explain how to apply personalized treatment strategies using a multidisciplinary approach to effectively manage systemic mastocytosis
    • Recall the latest data for new and emerging treatments for systemic mastocytosis and evaluate their potential impact on the clinical management of systemic mastocytosis in the future
    Dermatological Conditions
    Watch Time: 38 mins
    touchMDT
    Establishing treatment and care pathways for patients with prurigo nodularis: A patient-centric focus from multidisciplinary perspectives
    CE/CME ACCREDITED Dr Manuel Pereira, Ms Sailaja Maganti, Prof. Anthony Bewley, Prof. Martin Metz Translations available:

    Select a discussion in our hub to watch our multidisciplinary experts, including a patient advocate, share important perspectives on the need to establish patient-centric treatment and care pathways for the management of prurigo nodularis.

    Learning objectives
    Learning Objectives
    • Define the burden of disease and unmet need for prurigo nodularis
    • Recall and apply the range of treatment and management options available for prurigo nodularis, including approved treatments, appropriately
    • Implement a holistic, multidisciplinary approach to care for prurigo nodularis, taking into account patient’s individual circumstances and needs
    touchMEETING HIGHLIGHTS
    ADVENT at EADV 2023: Expert insights on AD in children, PN, and CSU
    For HCPs in: Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Canada, China, Colombia, Costa Rica, Denmark, Dominican Republic, Ecuador, Egypt, Finland, France, Germany, Guatemala, Hong Kong, Hungary, Iceland, Italy, Kuwait, Lebanon, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Singapore, South Korea, Spain, Sudan, Sweden, Taiwan, Thailand, The Netherlands, and UAE
    View Time: 8 mins Sponsored content

    Watch highlights of three ADVENT symposia presented at EADV 2023

     

    MAT-GLB-2303418 V1.0 12/2023
    Date of Preparation: December 2023
    Paediatric Dermatology, Atopic Dermatitis, Dermatological Conditions, Immunology
    Watch Time: 38 mins
    touchPANEL DISCUSSION
    Paediatric atopic dermatitis: Evolving strategies for improved management
    CE/CME ACCREDITED Dr Elaine Siegfried, Assist. Prof. Nives Pustišek, Prof. Andreas Wollenberg

    Watch three experts discuss how they manage moderate-to-severe atopic dermatitis in children.

    Learning objectives
    Learning Objectives
    • Recognize the burden of atopic dermatitis in children, their families and caregivers and its impact on quality of life, particularly in moderate-to-severe disease
    • Summarize the latest data for systemic treatment options in children and adolescents with moderate-to-severe atopic dermatitis
    • Assess how continuity of care in children and adolescents impacts long-term symptom control
    Dermatological Conditions
    Watch Time: 49 mins
    touchPANEL DISCUSSION
    Prurigo nodularis: Improving awareness, diagnosis, management and quality of life
    CE/CME ACCREDITED Prof. Sonja Ständer, Dr Shawn Kwatra, Prof. Matthias Augustin Translations available:

    Watch three experts discuss the symptom burden faced by patients with prurigo nodularis, and how clinicians can optimize diagnosis and treatment of the disease. **Now including 2023 UPDATE (scroll to chapter 5)**

    Learning objectives
    Learning Objectives
    • Define the burden of disease and unmet need for prurigo nodularis
    • Identify the differential diagnoses for patients with prurigo nodularis and recall the range of treatment and management options available
    • Evaluate the emerging treatment options for the management of prurigo nodularis and how these may impact current clinical practice
    touchMEETING HIGHLIGHTS
    Latest insights on atopic dermatitis and prurigo nodularis
    For HCPs in: Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Canada, Chile, China, Colombia, Costa Rica, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Lebanon, Macau, Malaysia, The Netherlands, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, and UAE
    View Time: 5 mins Sponsored content

    Key updates from 2 cutting-edge expert symposia presented at WCD 2023

     

    MAT-GLB-2304709 v1 10/2023
    Date of Preparation: October 2023
    Dermatological Conditions
    Developed by Touch
    Claudia De La Cruz, Dermatology Meeting News 2023: Effisayil 1 – a phase 2 study of spesolimab for generalized pustular psoriasis
    Watch Time: 6 mins

    Effisayil 1 (NCT03782792) was a randomised, double-blind, placebo-controlled phase 2 study that investigated the efficacy and safety of spesolimab in generalized pustular psoriasis (GPP). touchIMMUNOLOGY were delighted to speak with Dr. Claudia De La Cruz (Clínica Dermacross, Santiago, Chile) to discuss the aims, design and findings from Effisayil 1 and the impact spesolimab has already […]

    Dermatological Conditions
    Dedee Murrell Pemphigus
    Developed by Touch
    Dedee Murrell, Dermatology Meeting News 2023: Pemphigus – prevalence, clinical presentations & impact on quality of life
    Watch Time: 9 mins

    Pemphigus is a rare autoimmune blistering disease, which results in painful blisters on the skin or mucous membranes, severely impacting patient quality of life. It was a pleasure to talk with Prof. Dedee F. Murrell (St George Hospital Campus, Kogarah, Sydney, Australia) around the prevalence, clinical presentations and impact of pemphigus on patient quality of […]

    In Partnership with...
    Useful Links:
    About us Society Partners Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchIMMUNOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup